Condition: Colorectal Cancer · Sponsor: Nizhny Novgorod Regional Clinical Oncology Center
All patients with locally advanced colorectal cancer after radical surgical intervention who have not previously received systemic antitumor treatment will be randomized into two groups receiving fluoropyrimidines in mono-regimen and in combination with oxaliplatin. Main objectives: * to compare the 3-year disease-free survival and 5-year overall survival rates in the two groups. * to identify, through a comprehensive geriatric assessment among elderly patients, the groups that benefit most from adjuvant chemotherapy. Patients will be treated until progression of the process is detected or the maximum effect of therapy is reached (the longest duration of treatment is 6 months).
This description comes directly from the study's public registry record.
Arina Datsyuk · +79049209496 · doc70doc@yandex.ru
MIKHAIL OSIPOV · +79052075653 · ocipovmixail@mail.ru
Always discuss trial participation with your own doctor first.
| Research Institute of Clinical Oncology "Nizhny Novgorod Regional Clinical Oncological Dispensary" | Nizhny Novgorod, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06888843